DEPENDENCE OF CARDIOTROPHIN-1 ON BIOCHEMICAL AND HORMONAL FACTORS IN PATIENTS WITH COMORBID PATHOLOGY: ARTERIAL HYPERTENSION, DIABETES MELLITUS TYPE 2 AND OBESITY

Authors

DOI:

https://doi.org/10.21856/j-PEP.2023.2.01

Keywords:

Cardiotrophin-1, comorbid pathology, type 2 diabetes mellitus, arterial hypertension, obesity, regression analysis

Abstract

The prevalence of arterial hypertension, type 2 diabetes mellitus (type 2 DM), and obesity is constantly increasing worldwide. Today, a complex of factors, which primarily include chronic emotional stress, pandemics of infectious diseases, military conflicts, have led to a significant increase in chronic non-communicable diseases.

The aim of the study. To determine the dependence of Cardiotrophin-1 on a number of biochemical and hormonal indicators in patients with arterial hypertension, type 2 DM, and obesity, representatives of the Ukrainian population.

Materials and methods. The study included 211 patients aged 49 to 65 years, who were divided into groups depending on the pathology: patients with arterial hypertension – 49 persons, Group I; patients with arterial hypertension in combination with class 1 obesity – 54 persons, Group 2; patients with arterial hypertension in combination with type 2 DM – 57 persons, Group 3; patients with arterial hypertension, type 2 DM, class 1 obesity – 51 persons, Group 4; as well as 20 persons – the Control group.

Determination of the content of Cardiotrophin-1, catestatin, leptin, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), N-terminal brain natriuretic peptide (NT-proBNP), 25-OH of common vitamin D (Vitamin D3), blood levels was carried out by enzyme immunoassay on Labline-90 analyzer (Austria), using commercial test systems manufactured by FineTest (ELISA, China), BT LAB (ELISA, China), DBC (ELISA, China), Elabscience (ELISA, Canada), Monobind Inc. (ELISA, USA).

Statistical data analysis was performed, using the statistical software package Statistica, 12 (Stat Soft Inc, USA), Microsoft Office Excel 2013. Data are shown as mean (M) and standard deviations (δ). An error of less than 5% was considered to be significant (p<0.05). Stepwise regression analysis was used to determine the extent of exposure of the studied indicators to the CTF-1 level, with its effectiveness assessed by one-way analysis of variance (ANOVA).

Results. Thus, the study indicates that comorbid patients with arterial hypertension, type 2 DM, and obesity are predicted to develop complications from the cardiovascular system and Cardiotrophin-1 is a marker of their development. In the examined patients as a whole, the level of Cardiotrophin-1 is closely related to the peptide-hormonal complex: catestatin, leptin, cystatin C, brain natriuretic peptide, and lipocalin associated with neutrophil gelatinase.

Conclusions: The serum concentration of Cardiotrophin-1 in patients with arterial hypertension increases significantly in a progression with the rate of accession of comorbid pathology and its severity. The Cardiotrophin-1 level in patients with comorbid pathology is affected by catestatin, leptin, cystatin C, NT-pro BNP, as well as the level of triglycerides, HDL-C, creatinine, and BMI. Cardiotrophin-1 can be considered as a universal biomarker for the development and progression of cardiovascular disorders in patients with comorbid pathology of arterial hypertension, type 2 DM, and obesity.

References

Hadjkacem F, Triki F, Frikha H, et al. Ann Cardiol Angeiol (Paris) 2022;71(3): 136-140. doi: 10.1016/j.ancard.2021.10.018

Teck J. Prim Care 2022;49(2): 275-286. doi: 10.1016/j.pop.2021.11.004

El Meouchy P, Wahoud M, Allam S, et al. Int J Mol Sci 2022;23(20): 12305. doi: 10.3390/ijms232012305

Kolesnyk MYu. Odesa Med J 2014;(6): 65-71.

Kolesnyk MYu. Actual Probl Modern Med 2015;15(1): 110-115.

Sokolova MV. Clin Experim Pathol 2019;18(3): 70-77.

Matohniuk MO, Lymanskyi OV, Zhebel VM, Starzhynska OL. Bull Vinnytsia Nat Med Un-ty 2019;23(1): 172-177.

Matohniuk MO, Zhebel VM, Kulchevych LV, Shevchuk OK. Bull Vinnytsia Nat Med Un-ty 2020;24(3): 460-464.

García-Cenador MB, Lopez-Novoa JM, Díez J, García-Criado FJ. Curr Med Chem 2013;20(2): 246-256. doi:10.2174/092986713804806702

Moreno-Aliaga MJ, Romero-Lozano MA, Castaño D, et al. Adipocyte 2012;1(2): 112-115. doi:10.4161/ adip.19696

Gamella-Pozuelo L, Fuentes-Calvo I, Gómez-Marcos MA, et al. Medicine (Baltimore) 2015;94(30): e1218. doi:10.1097/ MD.0000000000001218

Zalewska E, Kmieć P, Sworczak K. Front Cardiovasc Med 2022;9: 909480. doi: 10.3389/fcvm.2022.909480

Bozic J, Kumric M, Ticinovic Kurir T, et al. Biomedicines 2021;9(12): 1757. doi: 10.3390/biomedicines9121757

Mahata SK, Kiranmayi M, Mahapatra NR. Curr Med Chem 2018;25(11): 1352-1374. doi: 10.2174/0929867324666170425100416

van der Laan SW, Fall T, Soumaré A, et al. J Am Coll Cardiol 2016;68(9): 934-945. doi: 10.1016/j.jacc.2016.05.092.

Ferguson TW, Komenda P, Tangri N. Curr Opin Nephrol Hypertens 2015;24(3): 295-300. doi: 10.1097/MNH.0000000000000115.

Helmersson-Karlqvist J, Lipcsey M, Ärnlöv J, et al. Heart 2022;108(4): 279-284. doi: 10.1136/heartjnl-2020-318860

Malachias MVB, Wijkman MO, Bertoluci MC. Diabetol Metab Syndr 2022;14(1): 64. doi: 10.1186/s13098-022-00837-6

Malachias MVB, Jhund PS, Claggett BL, et al. J Am Heart Assoc 2020;9(19): e017462. doi: 10.1161/JAHA.120.017462

Prausmüller S, Resl M, Arfsten H, et al. Cardiovasc Diabetol 2021;20(1): 34. doi: 10.1186/s12933-021-01221-w

Poetsch MS, Strano A, Guan K. Front Endocrinol (Lausanne) 2020;11: 354. doi: 10.3389/fendo.2020.00354

Pereira S, Cline DL, Glavas MM, et al. Endocr Rev 2021;42(1): 1-28. doi: 10.1210/endrev/bnaa027

Liew CH, Sim WH, Low EZ, Chan BCM. Ir J Med Sci 2022;190(1): 441-442. doi: 10.1007/s11845-020-02288-2

Miteva K, Baptista D, Montecucco F, et al. Sci Rep 2020;10(1): 5791. doi: 10.1038/s41598-020-62596-6

López-Andrés N, Rousseau A, Akhtar R, et al. Hypertension 2012;60(2): 563-573. doi: 10.1161/HYPERTENSIONAHA.112.194407

Downloads

Published

2023-06-14

How to Cite

Dunaieva, I., & Bilovol, O. (2023). DEPENDENCE OF CARDIOTROPHIN-1 ON BIOCHEMICAL AND HORMONAL FACTORS IN PATIENTS WITH COMORBID PATHOLOGY: ARTERIAL HYPERTENSION, DIABETES MELLITUS TYPE 2 AND OBESITY. Problems of Endocrine Pathology, 80(2), 7–13. https://doi.org/10.21856/j-PEP.2023.2.01

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.